Quick Takeaways
- PMCB - PharmaCyte Biotech, Inc. has 15 insiders with reported activity on this page.
- Net insider value flow over the last year: +$128,708.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 15 Insiders of PharmaCyte Biotech, Inc.
- Symbol
- PMCB on Nasdaq
- Location
- Las Vegas, NV
What Changed
- Buy value: $128,708; sell value: $0.
- Net share flow: +160,000.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to buying over the last 12 months. Net value: +$128,708.
Buys
$128,708
Shares: 160,000
Insiders: 2
Sells
$0
Shares: 0
Insiders: 0
Net
+$128,708
Shares: +160,000
Insiders: 2
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 160,000 | 0 | $128,708 | $0 | +$128,708 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
PharmaCyte Biotech, Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Joshua Silverman | CEO and President, Director | $397,694 | +$80,476 | +25% | Mixed | 05 Jan 2026 |
| Jonathan Schechter | Director | $162,393 | +$48,232 | +42% | Filing P/S | 31 Mar 2026 |
| Robert Weinstein | Director | $42,075 | Mixed | 31 Mar 2026 | ||
| Michael M. Abecassis | Director | $23,417 | Mixed | 31 Mar 2026 | ||
| Wayne Remell Walker | Director | $21,037 | Mixed | 31 Mar 2026 | ||
| Carlos A. Trujillo | Chief Financial Officer, Director | Mixed | 20 Nov 2023 | |||
| Matthias Loehr | Director | Mixed | 31 Mar 2022 | |||
| Daniel Stuart Farb | Director | Mixed | 28 Dec 2022 | |||
| Daniel Allen | Director | Mixed | 28 Dec 2022 | |||
| Gerald W. Crabtree | Chief Science Officer, Director | Mixed | 10 Aug 2021 | |||
| Thomas C. K. Yuen | Director | Mixed | 10 Aug 2021 | |||
| Jack E. Stover | Director | Mixed | 15 Aug 2022 | |||
| Thomas Liquard | Director | Mixed | 10 Aug 2021 | |||
| Kenneth L. Waggoner | Chairman, CEO, Pres and GC, Director | Mixed | 10 Aug 2021 | |||
| Raymond Cf Tong | Director | Mixed | 10 Aug 2021 |
Top shareholders of PharmaCyte Biotech, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Ayrton Capital LLC |
13D/G
|
— |
9.9%
|
774,100
|
$967,625 | $0 | 31 Dec 2024 | |
| INTRACOASTAL CAPITAL, LLC |
13D/G
|
Mitchell P. Kopin |
5%
|
532,254
|
$484,351 | $0 | 31 Dec 2025 | |
| Joshua Silverman |
3/4/5
|
CEO and President, Director |
4.4%
|
466,250
|
$397,694 | +$80,476 | 05 Jan 2026 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
3.4%
|
359,547
|
$239,243 | — | 31 Mar 2026 | |
| Jonathan Schechter |
3/4/5
|
Director |
—
mixed-class rows
|
311,670
mixed-class rows
|
$162,393 | +$48,232 | 31 Mar 2026 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.8%
|
195,660
|
$130,200 | — | 31 Mar 2026 | |
| Robert Weinstein |
3/4/5
|
Director |
—
mixed-class rows
|
160,420
mixed-class rows
|
$42,075 | — | 31 Mar 2026 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.53%
|
56,500
|
$37,595 | — | 31 Mar 2026 | |
| XTX Topco Ltd |
13F
|
Company |
0.49%
|
52,362
|
$34,842 | — | 31 Mar 2026 | |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.48%
|
51,467
|
$34,226 | — | 31 Mar 2026 | |
| Virtu Financial LLC |
13F
|
Company |
0.35%
|
37,532
|
$25,000 | — | 31 Mar 2026 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.33%
|
35,601
|
$23,689 | — | 31 Mar 2026 | |
| Michael M. Abecassis |
3/4/5
|
Director |
—
mixed-class rows
|
142,262
mixed-class rows
|
$23,417 | — | 31 Mar 2026 | |
| Wayne Remell Walker |
3/4/5
|
Director |
—
mixed-class rows
|
139,795
mixed-class rows
|
$21,037 | — | 31 Mar 2026 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.25%
|
27,009
|
$17,971 | — | 31 Mar 2026 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.23%
|
24,741
|
$16,000 | — | 31 Mar 2026 | |
| VANGUARD FIDUCIARY TRUST CO |
13F
|
Company |
0.22%
|
23,452
|
$15,596 | — | 31 Mar 2026 | |
| EQUITEC PROPRIETARY MARKETS, LLC |
13F
|
Company |
0.21%
|
22,227
|
$14,790 | — | 31 Mar 2026 | |
| SIMPLEX TRADING, LLC |
13F
|
Company |
0.19%
|
19,940
|
$13,260 | — | 31 Mar 2026 | |
| TWO SIGMA SECURITIES, LLC |
13F
|
Company |
0.15%
|
16,360
|
$10,886 | — | 31 Mar 2026 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.11%
|
11,530
|
$7,672 | — | 31 Mar 2026 | |
| Ground Swell Capital, LLC |
13F
|
Company |
0.11%
|
11,527
|
$7,670 | — | 31 Mar 2026 | |
| COMMONWEALTH EQUITY SERVICES, LLC |
13F
|
Company |
0.1%
|
10,313
|
$6,860 | — | 31 Mar 2026 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.05%
|
4,889
|
$3,253 | — | 31 Mar 2026 | |
| UBS Group AG |
13F
|
Company |
0.04%
|
4,519
|
$3,005 | — | 31 Mar 2026 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0.02%
|
1,785
|
$1,188 | — | 31 Mar 2026 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0%
|
302
|
$200 | — | 31 Mar 2026 | |
| Sachetta, LLC |
13F
|
Company |
0%
|
14
|
$10 | — | 31 Mar 2026 | |
| BFSG, LLC |
13F
|
Company |
0%
|
5
|
$4 | — | 31 Mar 2026 | |
| HARBOUR INVESTMENTS, INC. |
13F
|
Company |
—
class O/S missing
|
3
|
$2 | — | 31 Mar 2026 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
3
|
$2 | — | 31 Mar 2026 | |
| FINANCIAL CONSULATE, INC |
13F
|
Company |
0%
|
2
|
$2 | — | 31 Mar 2026 | |
| CALDWELL SUTTER CAPITAL, INC. |
13F
|
Company |
—
class O/S missing
|
2
|
$1 | — | 31 Mar 2026 | |
| Abound Wealth Management |
13F
|
Company |
0%
|
1
|
$1 | — | 31 Mar 2026 | |
| BlackRock, Inc. |
13F
|
Company |
0%
|
1
|
$1 | — | 31 Mar 2026 | |
| CWM, LLC |
13F
|
Company |
0%
|
1
|
$1 | — | 31 Mar 2026 | |
| Fortitude Family Office, LLC |
13F
|
Company |
—
class O/S missing
|
1
|
$1 | — | 31 Mar 2026 | |
| Johnson Financial Group, Inc. |
13F
|
Company |
0%
|
1
|
$1 | — | 31 Mar 2026 | |
| MCF Advisors LLC |
13F
|
Company |
0%
|
1
|
$1 | — | 31 Mar 2026 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
1
|
$1 | — | 31 Mar 2026 | |
| Daniel Allen |
3/4/5
|
Director |
—
class O/S missing
|
125,000
|
— | — | 28 Dec 2022 | |
| Daniel Stuart Farb |
3/4/5
|
Director |
—
class O/S missing
|
125,000
|
— | — | 28 Dec 2022 | |
| Carlos A. Trujillo |
3/4/5
|
Chief Financial Officer, Director |
—
class O/S missing
|
85,000
|
— | — | 20 Nov 2023 | |
| Kenneth L. Waggoner |
3/4/5
|
Chairman, CEO, Pres and GC, Director |
—
class O/S missing
|
20,600
|
— | — | 10 Aug 2021 | |
| Gerald W. Crabtree |
3/4/5
|
Chief Science Officer, Director |
—
class O/S missing
|
11,200
|
— | — | 10 Aug 2021 | |
| Matthias Loehr |
3/4/5
|
Director |
—
class O/S missing
|
3,004
|
— | — | 31 Mar 2022 | |
| Thomas C. K. Yuen |
3/4/5
|
Director |
—
class O/S missing
|
1,667
|
— | — | 10 Aug 2021 | |
| Thomas Liquard |
3/4/5
|
Director |
—
class O/S missing
|
1,667
|
— | — | 10 Aug 2021 | |
| Raymond Cf Tong |
3/4/5
|
Director |
—
class O/S missing
|
1,333
|
— | — | 10 Aug 2021 |
Recent Insider Transactions by Companies or Individuals for PharmaCyte Biotech, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Robert Weinstein | PMCB | Stock Option (Right to Buy) | Award | 119,170 | 119,170 | 31 Mar 2026 | Direct | |||
| Wayne R. Walker | PMCB | Stock Option (Right to Buy) | Award | 119,170 | 119,170 | 31 Mar 2026 | Direct | |||
| Jonathan Schechter | PMCB | Stock Option (Right to Buy) | Award | 119,170 | 119,170 | 31 Mar 2026 | Direct | |||
| Michael M. Abecassis | PMCB | Stock Option (Right to Buy) | Award | 119,170 | 119,170 | 31 Mar 2026 | Direct | |||
| Joshua N. Silverman | PMCB | Common Stock | Purchase | 10.6% | $33,316 | $0.8329 | 40,000 | 416,250 | 07 Jan 2026 | Direct |
| Jonathan Schechter | PMCB | Common Stock | Purchase | 11.6% | $16,872 | $0.8436 | 20,000 | 192,500 | 07 Jan 2026 | Direct |
| Joshua N. Silverman | PMCB | Common Stock | Purchase | 8.66% | $23,667 | $0.7889 | 30,000 | 376,250 | 06 Jan 2026 | Direct |
| Jonathan Schechter | PMCB | Common Stock | Purchase | 13.1% | $15,808 | $0.7904 | 20,000 | 172,500 | 06 Jan 2026 | Direct |
| Joshua N. Silverman | PMCB | Common Stock | Purchase | 9.49% | $23,493 | $0.7831 | 30,000 | 346,250 | 05 Jan 2026 | Direct |
| Jonathan Schechter | PMCB | Common Stock | Purchase | 15.1% | $15,552 | $0.7776 | 20,000 | 152,500 | 05 Jan 2026 | Direct |
| Robert Weinstein | PMCB | Common Stock | Tax liability | -45% | -33,750 | 41,250 | 12 Dec 2025 | Direct | ||
| Robert Weinstein | PMCB | Common Stock | Award | 75,000 | 75,000 | 12 Dec 2025 | Direct | |||
| Wayne R. Walker | PMCB | Common Stock | Tax liability | -45% | -16,875 | 20,625 | 12 Dec 2025 | Direct | ||
| Wayne R. Walker | PMCB | Common Stock | Award | 37,500 | 37,500 | 12 Dec 2025 | Direct | |||
| Joshua N. Silverman | PMCB | Common Stock | Tax liability | -45% | -258,750 | 316,250 | 12 Dec 2025 | Direct | ||
| Joshua N. Silverman | PMCB | Common Stock | Award | 575,000 | 575,000 | 12 Dec 2025 | Direct | |||
| Jonathan Schechter | PMCB | Common Stock | Tax liability | -33.8% | -67,500 | 132,500 | 12 Dec 2025 | Direct | ||
| Jonathan Schechter | PMCB | Common Stock | Award | 300% | 150,000 | 200,000 | 12 Dec 2025 | Direct | ||
| Michael M. Abecassis | PMCB | Common Stock | Tax liability | -43.1% | -16,875 | 22,292 | 12 Dec 2025 | Direct | ||
| Michael M. Abecassis | PMCB | Common Stock | Award | 2249.6% | 37,500 | 39,167 | 12 Dec 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.